Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Polycystic Ovary Syndrome 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Pancreatic Neoplasms 1Paclitaxel-induced Neuropathy 1Obesity 1Neoplasms 1Insulin Resistance 1Hyperandrogenism 1Hirsutism 1Dyslipidemias 1Agnosia 1AML 1

Interventions

Cisplatin 182Radiotherapy 81Paclitaxel 80Brachytherapy 74Carboplatin 72pembrolizumab 63Bevacizumab 40Surveys and Questionnaires 29Colposcopy 29Radiation 28Gemcitabine 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 27Topotecan 26Magnetic Resonance Spectroscopy 24Blood Specimen Collection 23human papillomavirus vaccine, L1 type 16, 18 22Nivolumab 22Drug Therapy 22Papillomavirus Vaccines 20atezolizumab 19Platinum 19Radiotherapy, Intensity-Modulated 18Biopsy 18Docetaxel 17Taxes 16Cyclophosphamide 16Early Intervention, Educational 151,2-diaminocyclohexaneplatinum II citrate 15Methods 14fludarabine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Magnesium × Clear all
NCT02446652 2025-05-29

Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer

National Institute of Cancerología

Phase 3 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡